Correspondence Apr. 17 2024
Committee: Women and Equalities CommitteeFound: , speeding up diagnosis and treatment .
Mentions:
1: Andrew Western (Lab - Stretford and Urmston) care to be free for cancer patients for five years from diagnosis, or until the end of life, if the - Speech Link
Mentions:
1: Oliver Heald (Con - North East Hertfordshire) For example, the health benefits of AI have already been mentioned, such as in the diagnosis of bowel - Speech Link
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to prioritise research into variation of the prevalence of prostate cancer among different ethnic groups.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department welcomes the recently announced TRANSFORM trial which aims to save thousands of men each year by finding the best way to screen for prostate cancer across all ethnic groups. It will be spread across the United Kingdom, although final decisions on specific locations are yet to be taken. Men will be invited to participate via their general practices. This study, led by Prostate Cancer UK and supported by the Government among others, will also aim to address some of the inequalities that exist in prostate cancer diagnosis today by ensuring that one in ten of the trial participants will be black men, who are three times overrepresented compared to the population of men aged between 45 and 75 years old as based on 2021 census data.
More broadly, the National Institute for Health and Care Research (NIHR) funds research in response to proposals received from scientists and commissioned calls rather than allocating funding to specific disease areas. It welcomes funding applications for research into any aspect of human health, including prostate cancer. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality.
In addition, to raise awareness of prostate cancer in this group, Leicester’s Centre for BME Health has developed a toolkit in partnership with the NIHR with guidance on how to start conversations about prostate cancer and overcome barriers to diagnosis.
Oral Evidence Apr. 16 2024
Inquiry: NHS leadership, performance and patient safetyFound: We are better at diagnosing things like cancer, ADHD and mental health, so leaders need more capacity
Apr. 15 2024
Source Page: Supporting safer visiting in care homes during infectious illness outbreaksFound: (For example, smoking cessation, obesity, drug and alcohol dependency, dementia and cancer. ).
Apr. 15 2024
Source Page: Brain Tumour Research Funding: FOI releaseFound: The strategy takes a comprehensive approach to improving patient pathways, from prevention and diagnosis
Apr. 15 2024
Source Page: Brain Tumour Research Funding: FOI releaseFound: The strategy takes a comprehensive approach to improving patient pathways, from prevention and diagnosis
Asked by: Stephanie Peacock (Labour - Barnsley East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions she has had with NHS England on ensuring that cancer is (a) diagnosed and (b) treated as quickly as possible.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department engages in ongoing discussions with NHS England, and is taking steps to reduce cancer diagnosis and treatment waiting times across England. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity.
Recently, following ministerial approval, NHS England consolidated the cancer waiting times standards on 1 October 2023. This followed the clinically led review of standards across the National Health Service, which recommended consolidating cancer waiting times from 10 standards into three. The three standards are: the Faster Diagnosis Standard (FDS), ensuing a maximum 28-day wait for communication of a definitive cancer or non-cancer diagnosis for patients referred urgently, or those identified by NHS cancer screening; a maximum 62-day wait to first treatment from urgent general practitioner referral, NHS cancer screening, or consultant upgrade; and a maximum 31-day wait from the decision to treat to any cancer treatment starting, for all cancer patients.
To achieve the FDS target and early diagnosis, NHS England has implemented a non-symptom specific pathway for patients who present with non-specific symptoms, or combinations of non-specific symptoms, that can indicate several different cancers, and a Best Timed Practice Pathway to ensure patients are diagnosed or told that cancer is ruled out within 28 days of an urgent referral.